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Self-reported fatigue in patients with rheumatoid arthritis: 
Repeated cross-sectional analyses over a 15 year follow-up 
 
 
 
Objective.  To estimate the prevalence and longitudinal development of fatigue in a Norwegian 
cohort of 238 patients with long-standing rheumatoid arthritis.  Additionally; to examine cross-
sectional association between fatigue and measures of disease activity, self-reported health status 
and damage in our cohort. 
Methods.  A cohort of 238 patients with rheumatoid arthritis has been followed since 1992. The 
prevalence of self-reported fatigue was determined and clinical laboratory and radiographic data 
used in the present study were collected at 5, 10 and 15 years after baseline. The longitudinal 
development of fatigue was investigated in the 10 most fatigued, and the 10 least fatigued patients, 
in groups defined on the basis of the results from 2007. Linear regression analyses were performed 
to identify variables strongly associated with fatigue at the different time-points. The variables 
included were divided into eight categories, each reflecting important aspects of RA. From the 
categories with a significant relationship to fatigue, the strongest predictive variable was included in 
a stepwise multiple regression.  
Results.  The prevalence of clinically relevant fatigue (VAS ≥ 20 mm) was 70.1 % in 1997, 79.1 % 
in 2002 and 80.0 % in 2007. High levels of fatigue (VAS ≥ 50) were present in 41.2 %, 39.6 % and 
41.9 % at years 1997, 2002 and 2007, respectively. The longitudinal development of fatigue in the 
10 most fatigued, defined by the VAS-scores from 2007, showed an increasing trend. Among the 10 
least fatigued, also based on the data from 2007, the fatigue levels showed a more heterogeneous 
picture.  
At years 5 and 15, the categories showing a significant relationship with fatigue in the linear 
regression analyses were disease activity, pain, physical function, psychosocial status and general 
health. A similar relationship was found at the 10 year follow-up, except that there was also 
significant correlations between fatigue and measures of damage. The final models from 1997, 2002 
and 2007 explained 41.7 %, 46.9 % and 26.8 % of the variance of fatigue, respectively.  
Conclusion. The prevalence of clinically important and high levels of fatigue remained stable in the 
course of the follow-ups in our cohort of patients with rheumatoid arthritis. Fatigue appears to be 
mainly linked to pain, general health and psychosocial status, and only to a lesser extent to disease 
activity. 
3 
 
 
Introduction 
 
Rheumatoid arthritis is a chronic, inflammatory disorder, with a high impact on all aspects of 
health, as described in the definition presented by the World Health Organization in 1948.  Part of 
this impact is constituted by fatigue, one of the many important symptoms of rheumatoid arthritis.  
It can occur as a prodromal symptom or as a precursor to increased arthritis disease activity [1]. 
 A consensus definition of fatigue is not yet presented, but Piper [2] has defined chronic 
fatigue as something that “is perceived as unpleasant, unusual, abnormal or excessive whole-body 
tiredness, disproportionate to or unrelated to activity or exertion and present for more than one 
month. Chronic fatigue is constant or recurrent, it is not dispelled easily by sleep or rest and it can 
have profound negative impact on the person’s quality of life.” 
In patients with RA, fatigue can be severe, and is besides pain the most troublesome 
symptom to handle [3-6].  In a Dutch study exploring patient`s experience of fatigue, almost half of 
the respondents attribute having a daily episode of fatigue with a greater impact on daily life than 
pain [4].  Patients from UK add to the description that fatigue is a frequent, extreme and 
multidimensional experience, with consequences that affect every aspect of life and lead to major 
disruption and distress [5]. In the elaboration of the preliminary Rheumatoid Arthritis Impact of 
Disease Score, patients from 10 different European countries ranked fatigue as the third most 
import domain to be included in the score [9]. 
  Patients believe that RA fatigue is caused by inflammation, co-morbidity, age and disability, 
but frequently it occurs without a specific reason [3, 4].  It can be unexpected, sudden of onset and 
without a specific pattern, which makes it especially frustrating and difficult for the patients to 
handle. Patients describe their fatigue before the diagnosis of RA as explainable and spontaneously 
resolving, whilst fatigue after the diagnosis is far more complex [3, 7, 10]. 
Fatigue has been given a lot of attention by researchers, clinicians and patients during the 
last decades.  Fatigue has proved to be an important outcome measure [7] that needs to be addressed 
by professionals in the same way as pain and disability [8]. 
 The opinion of fatigue as a complex clinical feature is shared by a lot of rheumatologists and 
other health care professionals who work with chronic diseases.  The exact causes, as well as the 
proper way to treat fatigue, are so far not entirely clear.  Clinical measures strongly associated with 
fatigue may become important targets of treatment. 
 Both patient centered and disease centered variables were included in our analyses in order 
to elucidate whether fatigue is a symptom that is associated with soluble biomarkers and disease-
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specific measures, or a sensation that needs to be addressed in a more holistic and personal 
perspective. The aim of this study is to determine the prevalence and longitudinal development of 
fatigue, and to identify the variables most strongly associated with self-reported fatigue in a cohort 
of individuals with RA.  
  
 
 
Materials and methods 
 
Patient sample   
 
At baseline in 1992, patients aged 20-70 years with RA, according to the ACR 1987 criteria [11], of 
less then 4 years duration were identified from the registry of the Department of Rheumatology, 
Diakonhjemmet Hospital, and from the registry of Akershus County Department of Rheumatology.  
326 patients were invited to join the study, 268 (82%) accepted, and 238 met the inclusion criteria. 
Criteria of entry and exclusion were those set by the EURIDISS project [12].  At baseline the mean 
age (SD) was 51.9 years (13.0), 73.5% were female and the mean disease duration was 2.3 years 
(1.1).  60.5% were anti CCP positive, 47.9% were IgM rheumatoid factor (RF) positive and 21% 
had extraarticular manifestations.  182 were re-examined after 5 yrs. Reasons for the loss of 56 
patients to the 5 yr follow-up were reluctance to participate further (n = 39), moving out of the area 
(n = 5) and death (n = 12). It has been shown earlier that the patients completing the 5-yr follow-up 
were younger than the non-completers (p = 0.01), but they were comparable for all other 
demographic and disease-specific features [13]. 149 were examined again after 10 years. After 15 
yrs, 108 patients participated, of whom 107 answered the questionnaires, whilst 75 declined to 
participate, and 56 patients were deceased.  
 
 
Assessment methods  
 
Collection of clinical, laboratory and radiographic data used in the present study were performed at 
5, 10 and 15 years after baseline. The data included in our analyses were divided into eight different 
categories, as shown in Tables 1, 2 and 3. 
  
Demographic variables 
Demographic variables included age, sex, marital status and education. Marital status was 
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dichotomized into levels 0 and 1 (0 = not married, divorced, widow/widower, 1 = married, living 
together). Education were also divided into two categories (0 = no university college or university 
education/no more education after completing senior high school, 1 = university college or 
university education). 
  
Measures of fatigue 
Fatigue was measured using a double anchored VAS labeled at one end, "Fatigue is no 
problem," and on the other end, "Fatigue is a major problem." The question read, "Have you had 
problems with fatigue/tiredness in the past week?" The range of the scale is 0 - 100, where 100 
represents major problems with fatigue and 0 means no fatigue at all [14]. The VAS fatigue is a 
simple generic instrument, measuring only one general dimension of the symptom [10, 14, 30].  
It is sensitive to change, well correlated to clinical variables [15], and Hewlett et al. [26] have 
identified evidence of reasonable validation for it in a systematic review of 23 scales in use.  
 
Measures of disease activity  
Disease activity was assessed by the Disease Activity Score (DAS 28) [16], tender joint counts 28, 
swollen joint counts 28 and the Ritchie Articular index.  
 The Disease Activity Score comprises tender and swollen joint counts from a 28 joint count, 
erythrocyte sedimentation rate (1
st
 hour; ESR), and patients' assessment of disease activity by a 
visual analog scale for general health (VAS, 0-100 mm scale, where 0 = no disease activity, 100 = 
extreme disease activity).  The 28 joint count is a reliable and valid measure for joint assessment. 
The examination needed is easy to perform, and it addresses the joints that are critically involved 
[17]. Prevoo et al [18] have found that the validity and reliability of traditional joint indices do not 
differ substantially, and thereby, because of their simplicity, the 28 joint indices are preferable. The 
tender and swollen joint counts were performed by one trained research nurse. 
 
Biomarkers  
Serum was frozen at each visit and later batch analyzed. The presence of IgM-RF was analyzed 
with the use of an enzyme-linked immunosorbent assay technique and World Health Organization 
standard reference for RF preparations [19, 20]. Patients with IgM-RF values of greater than or equal 
to 25 IU/ml were defined as RF-positive. IgG antibodies to cyclic citrullinated peptide (Anti-CCP) 
was also analyzed at each time. The analyses were performed using a second generation ELISA 
(INOVA Diagnostics®), and the results were considered positive above a cut-off value of 25/ml 
[21]. Anti-CCP is, as opposed to RF, a very sensitive measure in the making of the diagnosis of 
rheumatoid arthritis, and it has earlier been proved a strong predictor of disease course in early 
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rheumatoid arthritis [22]. 
Erythrocyte sedimentation rate (ESR) and CRP were also categorized as biological markers. 
Determination of the ESR and the CRP was carried out at the local laboratory at each of the follow-
ups.   
  
Damage 
 Radiographic damage was at the 5 and 10 year follow-ups scored according to the van der Heijde 
modification of the Sharp method. Sixteen joint areas were assessed for erosions (score 0-5) and 15 
areas were assessed for joint space narrowing (score 0-4) in each hand, rendering a potential 
maximum total score for both hands of 280. Conventional radiographs are available at 5 years, 
while radiographs at 10 and 15 years were digitized. Joint radiographs that could not be read (due to 
lack of visible joints on the radiographs or due to prior joint replacement/arthorodesis surgery) were 
given the last available score (last observation carried forward) [20]. 
In 2007, joint damage was evaluated using the rheumatoid arthritis articular damage score (RAAD 
score). The RAAD score is based on a clinical examination of 35 large and small joints (score range 
0-70), and has been shown to be a quick and feasible method for measuring long-term articular 
damage in large RA populations [23]. The examinations at the follow-ups were performed by a 
trained research nurse. 
  
Pain VAS  
Pain severity was assessed using a double anchored VAS labeled at one end, "No pain," and on the 
other end, "Unbearable pain." The question read, "How would you describe your regular pain 
during the past week?" The range of the scale is 0 - 100, where 100 equals worst imaginable pain 
and 0 being no pain at all. 
 
The Stanford Health Assessment Questionnaire (HAQ)  
The Stanford Health Assessment Questionnaire (HAQ) [14, 24], assessing functional status, was 
filled in by the patients themselves without any assistance.  The questionnaire consists of 20 
questions examining 8 dimensions of activities of daily living (dressing and grooming, getting up, 
eating, walking, hygiene, grip, reach and other activities).  For each item, there is a four-level 
difficulty scale that is scored from 0 to 3, representing normal/no difficulty (0), some difficulty (1), 
much difficulty (2), and unable to do (3).  The scores are averaged into an overall HAQ-DI score on 
a scale from zero (no disability) to three (completely disabled).  The scale has 25 possible values 
(i.e. 0, 0.125, 0.250, 0.375...), and the higher the score, the more disable the patient is.  The HAQ 
has been validated in Swedish, which is very similar to the Norwegian language. 
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The Short Form 36 Health Questionnaire 
The SF36 [14, 25] was also completed by the patients themselves. This questionnaire is designed as 
a generic indicator of health status for use in population surveys and evaluative studies of health 
policy, and has only more recently been used to complement disease-specific measures in clinical 
trials. It consists of 36 questions, grouped into eight multi-item subscales measuring general health 
(5 items), physical functioning (10 items), role limitations due to physical health (4 items),  bodily 
pain (2 items), vitality/energy/fatigue (4 items), social functioning (2 items), role limitations due to 
emotional problems (3 items) and mental health (5 items). Each scale is expressed with values from 
0 to 100, where a high score indicates good health. The subscales included in our analyses are 
general health, physical functioning, bodily pain, social functioning and mental health. SF-36 
vitality was excluded from our analyses because of its similarity to measures of fatigue [26]. 
  
Arthritis Impact Measurement Scale (AIMS) 
The AIMS [13, 14] is a multidimensional index that measures the health status of individuals with 
arthritis. It was developed in 1980, and consists of seven demographic items and 55 health status 
items, assessing physical, emotional and social well-being. The items are divided into nine scales: 
mobility, physical activity, dexterity, household activities, activities of daily living, social activities, 
anxiety, depression, and pain. The scores for each individual scale are transformed into a 0-10 scale, 
on which 10 equals worst possible health. Also, the patients' global assessment of the impact of 
arthritis was assessed by one item from the AIMS on a scale from 0 to 10. AIMS was used in both 
1997 and 2002, and we included the scales measuring pain, physical activity, mobility, social 
activity, anxiety, depression and impact in our analyses. 
  
Arthritis Impact Measurement Scale 2 (AIMS2) 
The AIMS2 [14] is an expanded and revised version of AIMS, and was used at the 15 year follow-
up. It is a multidimensional disease specific instrument with 78 items capturing information in 12 
areas of health (mobility level, walking and bending, hand and finger function, self-care tasks, arm 
function, household tasks, social activity, support from family and friends, pain, work, level of 
tension, mood). These 12 scales can be aggregated into five major dimensions, concerning physical 
functioning, social interaction, pain, work and affect. The score is ranged from 0 to 10, where 10 
equals worst possible health. AIMS2 also includes a separate question that addresses the patients' 
priorities for improvement in health, as well as a question about the total impact of RA. A short 
form of AIMS2 has been validated in Norwegian. The AIMS and the AIMS2 were compared, and 
the most similar scales from each of the questionnaires concerning pain, physical function, social 
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function/mental health and general health/energy were included in our analyses. From AIMS2 we 
included pain, physical, social interaction, affect and impact. 
  
The General Health Questionnaire (GHQ) 
The General Health Questionnaire [27, 28] is a standard measure of psychological distress. It was 
originally developed as a screening tool to detect those likely to have or be at risk of developing 
psychiatric disorders. It consists of 28 items assessing social withdrawal, anxiety, depression and 
somatic symptoms. Each item is accompanied by four possible responses, ranging from 0 to 3, 
yielding a total GHQ score between 0 and 84. Jenkinson and Fitzpatrick [27] has proven the GHQ to 
be a suitable instrument in assessing the impact of illness upon patients' lives, both in severely 
disabling disorders such as rheumatoid arthritis and milder conditions. In the current study, all four 
dimensions of the GHQ were included. 
 
   
Statistical analysis  
 
The following analyses were performed using SPSS14. The prevalence of fatigue at the 5, 10 and 
15 year follow-ups were calculated, after having defined clinically relevant fatigue to be VAS ≥ 20 
mm, and high levels of fatigue to be VAS ≥ 50 mm [29]. The longitudinal developments of the 10 
most and the 10 least fatigued patients, were visualized by continuous graphs over the previous 10 
years, using SPSS14 and Microsoft Excel. 
The independent variables included in the current study were entered into a scatterplot with 
fatigue, to check the relationship of fatigue to each of the variables, and in particular to see if there 
were any outliers who could contribute to a misleading result. Then, a linear regression analysis was 
performed for each of the independent variables, controlled for age and sex. The relationships 
between fatigue and level of education, and fatigue and marital status, were also investigated. The 
independent variables from each category showing the most significant correlation with fatigue, 
were then included in a stepwise multivariate regression analysis. In categories where two variables 
significantly correlated with fatigue shared the same level of significance, the variable with the 
highest R sq adjusted was included in further analyses. The stepwise multivariate regression 
analysis resulted in three final models from each time-point, including only variables with a 
significant contribution. All p-values equal to or less than 0.05 were considered statistically 
significant, and all tests were two-sided. 
Numbers of respondents in each of the different categories are presented in brackets in 
Tables 2, 3 and 4. Percentage of data missing at the three follow-ups ranged from 0 % to 37 % 
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(SF36 mental and general health at the 15 year follow-up). The average of data missing at each 
follow up, were 4.8 %, 2.0 % and 7.9 % at the 5, 10 and 15 year follow-up, respectively. The total 
average of missing data at all three follow-ups was 4.9 %. Cases were excluded in order to achieve 
the same number of patients being tested in each category. 
 All of the included patients gave written consents before participation, and the study was 
approved by the regional ethics committee. 
 
 
 
Results 
 
Prevalence of fatigue 
 
The prevalence of clinically relevant fatigue was present in 70.1 %, 79.1 % and 80.0 % of the 
patients, at the 5, 10 and 15 year follow-ups, respectively. High levels of fatigue were present in 
41.2 %, 39.6 % and 41.9 %. The results are shown in Table 1. 
 
 
 
Table 1. Prevalence of clinically relevant and high levels of fatigue  
   Clinically relevant fatigue  High levels of fatigue  
   (VAS ≥ 20 mm)    (VAS ≥ 50 mm)   
1997   70.1 %     41.2 % 
2002    79.1 %     39.6 % 
2007  80.0 %     41.9 % 
 
 
 
Longitudinal development 
 
The foregoing longitudinal development of fatigue in the 10 least (Figure 1), and the 10 most 
fatigued (Figure 2), based on the results from 2007, showed different patterns.  
 The 10 least fatigued. Most of the 10 patients with the lowest fatigue scores in 2007 had 
their highest scores in 2002. Three of these patients scored their own fatigue higher than 80 on the 
VAS at the 10 year follow-up. Three patients reported their highest score in 1997, two of them 
slightly below 70. All other patients scored their fatigue below 30 on the VAS at all three time-
points. 
 The ten most fatigued. In the 10 with the highest fatigue scores in 2007, the values showed 
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an increasing trend from 1997 to 2007. Among the 10 most fatigued, 5 patients reported their lowest 
scores in 2002. Only one of these 5 patients scored his or her fatigue above 80, whilst three of the 
least fatigued reached a similar level. The tendency in both 1997 and 2007 was on the other hand 
quite the opposite. Apart from one outlier, all of the scores were above 40. 
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Figure 1. Longitudinal development among the 10 least fatigued. The X-axis represents the time of the three follow-ups, whilst the Y-
axis represents levels of fatigue on a 100 mm VAS scale. 
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Figure 2. Longitudinal development among the 10 most fatigued. The X-axis represents the time of the three follow-ups, whilst the Y-
axis represents levels of fatigue on a 100 mm VAS scale. 
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Univariate analyses  
 
The results from the univariate analyses between fatigue and different variables, adjusted for age 
and sex, are presented in Tables 2, 3 and 4.  
 
Demographic variables  
Age and sex were not significantly correlated to fatigue at any time.  In spite of this, they were 
included in all of the analyses, to exclude any confounding effects of age and sex on the final 
results. 
 Education and marital status, controlled for age and sex, did not show a significant 
association with fatigue, and was therefore not included in further analyses.   
 
Disease activity  
Among the three chosen measures of disease activity, the DAS 28 was the measure with the most 
significant relationship to fatigue at the 5 (p = 0.01) and 10 year (p = 0.002) follow-ups, explaining 
4.0 % and the 7.0 % of the variance, respectively. Swollen joint count 28 was the only measure of 
disease activity with a significant relationship to fatigue at the 15 year follow-up (p = 0.02), 
explaining only 3.0 % of the variance.   
  
Damage 
Sharp scores were available from the 5 and 10 year follow-ups, but a significant association with 
fatigue was only found at the latter of these follow-ups (p = 0.03), explaining 4 % of the variance. 
RAAD scores were available at the 10 and 15 year follow-ups, but did not prove significant to 
fatigue at any of the time-points. 
  
Biomarkers  
No significant relationships were found between fatigue and any of the biological markers at any of 
the follow-ups. 
  
Pain 
All included measures of pain were significantly correlated to fatigue at all three follow-ups, 
sharing the same level of significance (p < 0.00) VAS pain was the measure with the strongest 
explanatory power towards fatigue at the 5 and 10 year follow-ups, explaining 22 % and 27 % of 
the variance, respectively. At the 15 year follow up, SF-36 pain was the measure with the highest 
explanatory power (24 %). 
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Physical function 
HAQ was the measure of physical function showing the most significant relationship to fatigue (p < 
0.00) at the 5 and 10 year follow-ups, explaining 17 % and 13 % of the variance, respectively. At 
the 15 year follow-up, SF-36 physical was the measure with the most significant relationship to 
fatigue (p < 0.00), explaining 18 % of the variance.  
  
Psychosocial status 
At the 5 and 15 year follow-up, SF-36 social function was the measure with the most significant 
relationship to fatigue (p < 0.00), explaining 23 % and 21 % of the variance, respectively. At the 10 
year follow-up, SF-36 mental health was the measure most strongly related to fatigue (p < 0.00), 
explaining 29 % of the variance. Apart from AIMS social activity at the 5 and 10 year follow-ups 
and AIMS social interaction at the 15 year follow-up, all variables included in this category showed 
a significant association with fatigue at all three follow-ups. 
 
General health 
Among the measures of general health, GHQ somatic was the measure with the strongest 
association with fatigue (p < 0.00) at the 5 and 15 years follow-up, explaining 34 % and 18 % of the 
variance, respectively. At the 10 year follow-up, SF-36 general health was the measure with the 
most significant relationship to fatigue (p < 0.00), explaining 33 % of the variance. All variables 
included in this category showed a significant association with fatigue at all three follow-ups. 
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Table 2. 5 year follow-up. Results from the univariate analysis, with VAS fatigue (n=177) as the dependent variable (controlled for 
age and sex). Number of respondents are presented in brackets behind each variable. 
 
    β 95% CI  for β p Adjusted R square 
Demographic variables 
Age (ctrl sex) (n=182)  0.11 -0.23 - 0.46 0.52  0,01 
Sex (ctrl age) (n=182)  8.82 -1.13 - 18.76 0.08  0.01 
Education (n=182)   -2.03 -11.84 - 7.78 0.68  0.003 
Marital status (n=182)  5.35 -5.21 - 15.90 0.32  0.01 
 
Disease activity 
DAS28 (n=172)   4.03 0.95 - 7.10 0.01  0.04 
Swollen joint    
count 28  (n=179)   -0.07 -1.01 - 0.86 0.88  0.002 
Tender joint 
count 28  (n=179)   0.74 0.02 - 1.45 0.04  0.03 
 
Damage 
Sharp score (n=150)  -0.14 -0.32 - 0.03 0.11  0.02 
 
Biomarkers 
Anti CCP (n=129)   0.01 -0.04 - 0.06 0.75  -0.01 
IgM RF (n=129    -0.05 -0.10 - 0.01 0.11  0.02 
CRP (n=179)   0.23 -0.24 - 0.70 0.33  0.01 
SR (n=177)   0.01 -0.27 - 0.29 0.93  0.002 
 
Pain 
VAS pain (n=178)   0.60 0.42 - 0.78 < 0.001  0.22 
SF36 pain (n=177)   -0.39 -0.55 - -0.23 < 0.001  0.14 
AIMS pain (n=175)   4.82 3.14 - 6.49 < 0.001  0.18 
 
Physical function 
HAQ (n= 179)   17.89 11.41 - 24.38 < 0.001  0.17 
SF36 physical function (n=178) -0.44 -0.62 - -0.26 < 0.001  0.14 
AIMS physical activity (n=179) -0.28 -2.12 - 1.56 0.76  -0.003  
AIMS mobility (n=174)  -0.81 -3.00 - 1.38 0.46  0.00 
 
Psychosocial status 
SF36 mental health (n= 175)  -0.70 -0.94 - -0.47 < 0.001  0.19 
SF36 social function (n= 176) -0.52 -0.68 - -0.37 < 0.001  0.23 
AIMS social activity (n=174)  -0.27 -2.90 - 2.36 0.84  -0.003 
AIMS depression (n=174)  7.85 3.56 - 10.35 < 0.001  0.21 
AIMS anxiety (n=173)  5.67 3.53 - 7.80 < 0.001  0.16 
GHQ social (n=178)  4.03 2.79 - 5.27 < 0.001  0.21  
GHQ depression (n=177)  3.11 2.05 - 4.16 < 0.001  0.19 
GHQ anxiety (n=179)  2.63 1.76 - 3.50 < 0.001  0.19 
 
General health 
SF36 general health (n=174)  -0.61 -0.79 - -0.42 < 0.001  0.22 
AIMS impact (n=177)  5.29 3.35 - 7.23 < 0.001  0.16 
GHQ somatic (n=179)  4.31 3.34 - 5.28 < 0.001  0.34 
 
DAS28 = Disease Activity Score 28, VAS = Visual Analogue Scale, SF36 = Short Form 36 Health Questionnaire, AIMS = Arthritis 
Impact Measurement Scale, GHQ = General Health Questionnaire.  
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Table 3. 10 year follow-up. Results from the univariate analysis, with VAS fatigue (n=139) as the dependent variable (controlled for 
age and sex). Number of respondents are presented in brackets behind each variable. 
 
    β 95% CI  for β p Adjusted R square 
Demographic variables 
Age (ctrl sex) (n=149)  0.05 -0.26 - 0.37 0.75  0,01 
Sex (ctrl age) (n=149)  9.18 -0.43 - 18.79 0.06  0.01 
Education (n=149)   3.20 -6.00 - 12.41 0.49  0.01 
Marital status (n=149)  -0.49 -9.57 - 8.60 0.92  0.004 
 
Disease activity 
DAS28 (n=147)   4.76 1.74 - 7.79 < 0.001 (0.002) 0.07 
Swollen joint    0.20 -0.59 - 0.99 0.61  0.01 
count 28 (n=148)   
Tender joint   0.93 0.32 - 1.55 < 0.001 (0.003) 0.07 
count 28 (n=148)   
 
Damage 
Sharp score (n=147)  -0.13 -0.24 - -0.01 0.03  0.04 
RAAD score (n=148)  -0.24 -0.74 - 0.26 0.35  0.01 
  
Biomarkers 
Anti CCP (n=146)   -0.03 -0.07 - 0.01 0.16  0.02 
IgM RF (n=146)   -0.03 -0.08 - 0.02 0.24  0.01  
CRP (n=147)   0.15 -0.35 - 0.64 0.56  0.01 
SR (n=148)   0.05 -0.30 - 0.41 0.77  0.01 
 
Pain 
VAS pain (n=140)   0.54 0.39 - 0.70 < 0.001  0.27 
SF36 pain (n=147)   -0.50 -0.65 - -0.34 < 0.001  0.23   
AIMS pain (n=142)   5.30 3.73 - 6.88 < 0.001  0.26   
 
Physical function 
HAQ (n=149)   13.86 7.64 - 20.07 < 0.001  0.13    
SF36 physical function (n=147) -0.35 -0.51 - -0.19 < 0.001  0.12 
AIMS physical activity (n=148) 4.89 2.45 - 7.32 < 0.001  0.11   
AIMS mobility (n=144)  2.35 0.48 - 4.21 0.01  0.05 
 
Psychosocial status 
SF36 mental health (n=144)  -0.75 -0.96 - - 0.55 < 0.001  0.29 (0.289) 
SF36 social function (n=147)  -0.54 -0.70 - - 0.38 < 0.001  0.26  
AIMS social activity (n=144)  1.92 -0.50 - 4.34 0.12  0.02  
AIMS depression (n=143)  7.42 5.00 - 9.83 < 0.001  0.22  
AIMS anxiety (n=141)  6.90 5.00 - 8.81 < 0.001  0.29 (0.288) 
GHQ social (n=146)  3.38 2.04 - 4.72 < 0.001  0.16 
GHQ depression (n=146)  3.07 1.77 - 4.37 < 0.001  0.14 
GHQ anxiety (n=147)  2.83 1.84 - 3.81 < 0.001  0.20 
 
General health 
SF36 general health (n=142)  -0.65 -0.81 - - 0.49 < 0.001  0.33  
AIMS impact (n=145)  5.51 3.91 - 7.10 < 0.001  0.26 
GHQ somatic (n=148)  3.63 2.67 - 4.60 < 0.001  0.30  
 
DAS28 = Disease Activity Score 28, RAAD score = Rheumatoid Athritis Articular Damage score,  VAS = Visual Analogue Scale, 
SF36 = Short Form 36 Health Questionnaire, AIMS = Arthritis Impact Measurement Scale, GHQ = General Health Questionnaire.  
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Table 4. 15 year follow-up. Results from the univariate analysis, with VAS fatigue (n=105) as the dependent variable (controlled for 
age and sex). Number of respondents are presented in brackets behind each variable. 
 
    β 95% CI  for β p Adjusted R square 
Demographic variables 
Age (n=108)   0.02 -0.02 - 0.07 0.28  -0.01 
Sex (n=108)   0.39 -0.83 - 1.62 0.53  -0.01 
Education (n=104)   -0.06 -1.14 - 1.02 0.91  -0.01 
Marital status (n=104)  -0.21 -1.35 - 0.92 0.71  -0.01 
 
Disease activity 
DAS28 (n=108)   0.42 -0.16 - 1.00 0.16  -0.003 
Swollen joint    
count 28 (n=108)   0.19 0.03 - 0.35 0.02  0.03 
Tender joint 
count 28 (n=108)   0.04 -0.10 - 0.19 0.54  -0.01 
 
Damage 
RAAD score (n=107)  0.05 -0.02 - 0.11 0.14  0.01 
   
Biomarkers 
Anti CCP (n=101)   0.003 -0.003 - 0.008 0.34  -0.01 
IgM RF (n=101)   0.002 -0.001 - 0.005 0.12  0.01 
CRP (n=107)   0.02 -0.01 - 0.06 0.14  0.01    
SR (n=108)   -0.01 -0.05 - 0.03 0.71  -0.01    
 
Pain 
VAS pain (n=105)   0.43 0.21 - 0.64 < 0.001  0.12 
SF36 pain (n=86)   -0.05 -0.07 - -0.03 < 0.001  0.24 
AIMS2 pain (n=105)  0.46 0.26 - 0.65 < 0.001  0.17 
 
Physical function 
HAQ (n=107)   1.49 0.76 - 2.23 < 0.001  0.12 
SF36 physical function (n=69)   -0.05 -0.07 - -0.02 < 0.001  0.18 
AIMS physical (n=105)  0.56 0.22 - 0.90 < 0.001  0.08  
 
Psychosocial status 
SF36 mental health (n=68)  -0.10 -0.18 - -0.02 0.02  0.06 
SF36 social function (n=88)  -0.06 -0.08 - -0.03 < 0.001  0.21 
AIMS2 affect (n=104)  0.79 0.45 - 1.12 < 0.001  0.17 
AIMS2 social interaction (n=104) 0.28 -0.07 - 0.62 0.11  0.01  
GHQ social (n=101)  0.28 0.06 - 0.50 0.01  0.05 
GHQ anxiety (n=100)  0.35 0.20 - 0.50 < 0.001  0.18 
GHQ depression (n=100)  0.32 0.13 - 0.51 < 0.001  0.09 
 
General health 
SF36 general health (n=68)  -0.05 -0.08 - -0.02 < 0.001  0.13 
AIMS impact (n=103)  0.82 0.27 - 1.37 < 0.001  0.07 
GHQ somatic (n=100)  0.34 0.20 - 0.48 < 0.001  0.18 
 
DAS28 = Disease Activity Score 28, RAAD score = Rheumatoid Athritis Articular Damage score, VAS = Visual Analogue Scale, SF36 
= Short Form 36 Health Questionnaire, AIMS = Arthritis Impact Measurement Scale, GHQ = General Health Questionnaire.  
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Stepwise multivariate regression analyses 
 
From each category, the variable with the lowest level of significance, and the highest R sq 
adjusted, given that the category contained measures with a significant relationship to fatigue (level 
0.05), were included in a stepwise multiple regression. The collinearity was less than 0.7 between 
all of the entered variables. There were no confounding effects of any of the variables entered in the 
stepwise multivariate regression analysis, measured by checking the changing of the β-values 
during the analyses.  
 The final models from all three follow-ups are presented in Tables 5, 6 and 7.  
 
Table 5. Final model, 5 year follow-up, 1997 
 β 95 % CI for β p Adjusted R square 
Age -0.02 -0.29 - 0.25 0.888 0.417 = 41.7 % 
 Sex 5.38 -2.29 - 13.06 0.168 
GHQ somatic 2.98 1.90 - 4.07 < 0.001 
SF36 social function -0.18 -0.34 - -0.01 0.035 
VAS pain 0.30 0.12 - 0.48 0.001 
     
 
 
Table 6. Final model, 10 year follow-up, 2002 
 β 95 % CI for β p Adjusted R square 
Age -0.18 -0.42 - 0.06 0.148 0.469 = 46.9 % 
 Sex 2.33 -5.00 - 9.67 0.530 
Das28 -3.54 -6.54 - -0.53 0.021 
VAS pain  0.32 0.14 - 0.50 0.001 
SF36 general health -0.39 -0.60 - -0.17 < 0.001 
SF36 mental health -0.46 -0.66 - -0.26 < 0.001 
     
 
Table 7. Final model, 15 year follow-up, 2007 
 β 95 % CI for β p Adjusted R square 
Age 0.02 -0.02 - 0.06 0.343 0.268 = 26.8 % 
Sex -0.07 -1.24 - 1.11 0.912 
SF36 social function -0.03 -0.06 - 0.00 0.041 
SF36 bodily pain -0.04 -0.06 - -0.01 0.007 
 
 
 
Discussion 
 
Our most important findings were that the prevalence of fatigue remained stable in the course of the 
follow-ups, whilst the longitudinal development of fatigue among the 10 most and the 10 least 
fatigued patients showed a more heterogeneous picture. Regression analyses indicated that 
measures of disease activity, damage, pain, physical function, psychosocial status and general health 
were significantly associated with fatigue. In the final multivariate models, measures of pain, 
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psychosocial status, general health and disease activity were significant contributors to explaining 
fatigue.  
The prevalence of clinically relevant and high levels of fatigue (Table 1) in the cohort 
remained more or less constant during the three follow-ups, a finding that is consistent with 
previous analyses, although they have not followed the levels of fatigue for more than one year [1, 8, 
31]. Belza [1] argues that fatigue, because of its noted stability over time, seems to have more 
characteristics that would be associated with a trait, rather than a state. 
Clinically relevant fatigue (VAS ≥ 20 mm) was present in 70-80 % of our cohort at all three 
follow-ups, whilst approximately 40 % experienced high levels of fatigue (VAS ≥ 50 mm). Pollard 
et al. [29] used the same levels of defining different degrees of fatigue, finding clinically relevant 
fatigue to be present in more than 80 % of a population of patients with RA, whilst high levels of 
fatigue were present in 50 %. Wolfe et al. [32], Belza et al. [33] and Mancuso et al. [31], using the 
VAS fatigue, the Multidimensional Assessment of Fatigue scale [26, 30] and the Fatigue Severity 
Scale [30], respectively, found similar frequencies of different levels of fatigue. 
In interpreting the results from the current analyses of prevalence, one has to consider the 
possible confounding effects of the patients dropping out. Of the 238 patients included at baseline, 
only 108 attended the 15 year follow-up. During the 15 years of data collection 75 patients have 
declined to participate, and 56 patients are deceased. It is hard to determine whether the patients 
declining to participate or the patients deceased would have given different results, considering the 
heterogeneous continuous development of fatigue, as illustrated in Figures 1 and 2. It is possible 
that the patients declining to participate were too fatigued to participate any longer, or that the most 
fatigued were the ones that now are deceased. Levels of fatigue may on the other hand be 
completely unrelated to patients' willingness to participate. 
To a certain extent, Figures 1 and 2 gives the impression that the fatigued get more fatigued, 
whilst the least fatigued gets less fatigued. In our cross-sectional approach, it is not possible to 
determine whether these 20 patients reflect the true situation in our cohort. In order to examine this, 
mixed modeling would have been a suitable method. Thus, given the limitations of the current 
analyses, the graphs should merely be considered as illustrations on how levels of fatigue may 
develop over time in individual patients. 
The clinical variables included in our analyses were not equally powerful in explaining 
variance in fatigue (tables 1, 2 and 3). In keeping with previous reports [1, 8, 29, 32-40], pain, general 
health and psychosocial factors were consistently the categories most strongly related to fatigue at 
all three follow-ups. We also found a significant correlation of fatigue to measures of physical 
function, disease activity and damage. With the exception of DAS-28 at the 10 year follow-up, none 
of these variables appeared to be significant predictors of fatigue in the multivariate regression 
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analyses.  
 The final models from each of the follow-ups differed regarding included variables as well 
as ability towards explaining fatigue (Table 5, 6 and 7). The model as a whole at the 15 year follow-
up explained only 26.8 % of the variance of fatigue, as opposed to 41.7 % and 46.9 % at the 5 and 
10 year follow-ups, respectively. Such discrepancies between the models may indicate confounding 
effects of highly correlated variables, or that the association between fatigue and rheumatoid 
arthritis has become weaker during our follow-ups, or that we have not included all the relevant 
variables or simply that the disease has become milder [41]. In comparison with other studies 
evaluating fatigue at different disease durations, we did not find a similar pattern regarding the 
ability towards explaining fatigue. Huyser et al. [37] investigated correlates of fatigue in a 
population with a mean disease duration of 12.9 years, which resulted in a final model explaining 
49 % of the variance of fatigue. Accordingly; Belza et al. [33] found different variables to explain 
61 % of the variance of fatigue in patients with average disease duration of 18 years, predominantly 
females (75 %). These studies differ from the current regarding included variables, thus no rigid 
conclusions should be drawn based on the explanatory powers only. However, the findings of 
Huyser and Belza suggest that there is no evidence of fatigue loosing its association with 
rheumatoid arthritis in the course of the disease. 
 Concerning bivariate correlation in our final models, there will indubitably be some overlap 
in the explaining of fatigue. However, collinerarity diagnostics indicated no competing 
dependencies between any of the included variables. According to commonly used cut-off points for 
determining the presence of multicollinearity, acceptable levels of tolerance were set at above 0.4 
[42], and corresponding levels of bivariate correlation at less than 0.7 [43]. In the current study, the 
lowest level of tolerance was 0.44, whilst the highest bivariate correlation was 0.64. Based on these 
results, we have not violated the multicollineratiry assumption. 
In spite of the dissimilarities of the explanatory powers of the different final models, the 
strong explanatory power of pain was a common denominator through all three follow-ups. In the 
univariate analyses, pain explained more than 20 % of the variance of fatigue at all three time-
points. Pain was the only variable included in the final model at all three follow-ups.  The evidence 
of the strong association between pain and fatigue, irrespective of disease duration, is in accordance 
with many previous studies [1, 29, 31-40, 44, 45]. 
While demographic variables appear not to be significant factors in our correlation analyses, 
Belza et al. [33] and Hyuser et al. [37] found that female gender made a significant contribution to 
the explanation of fatigue. As distinct from the current study, Belza et al. and Huyser et al. used the 
Multidimensional Assessment of Fatigue scale and the Piper fatigue Self-Report scale (PFS) [30], 
respectively, to measure the degree of fatigue among the patients. Compared to the VAS fatigue, 
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these scales are more extensive, evaluating several dimensions of fatigue [15, 30], making different 
correlations more likely.  
Also, biological markers (IgM RF, anti-CCP, CRP, ESR) were not significantly associated 
with fatigue, a finding that is consistent with results from several previous studies [1, 8, 32, 33, 37]. 
However, Davis et al. [46] has found heightened proinflammatory cytokine activity in RA patients at 
risk for fatigue symptoms.  
 Our study is limited by the relatively low number of patients included, and the repeated 
analyses do not compensate this fact. If the group had been larger, we may have identified 
biological markers or measures of disease activity as significant correlates of fatigue. Also, some 
variables previously shown to be significantly correlated to fatigue were not included in the current 
analyses. These variables are self-efficacy towards coping with RA and towards asking for help, 
learned helplessness, comorbid conditions and quality of sleep [1, 31, 32, 33, 34, 37]. We chose early 
to limit our investigation to certain dimensions of rheumatoid arthritis, and thus some important 
variables were excluded. 
Another limitation of the current study is the use of a simple one-dimensional measure of 
fatigue.  In addition, we did not have measures of fatigue from the baseline of the study.  
One of the major problems in investigating characteristics of fatigue is that there is no “gold 
standard” definition, nor is there ever likely to be [30]. It is a big challenge to make sure that the 
patients have the same perception of fatigue as clinicians and researchers do. Some patients may 
apprehend it as tiredness or sleepiness rather than a more typical experience of fatigue. The use of 
extensive measures of fatigue may diminish these problems. 
Cognitive behavioral therapy, aerobic training and some anti-rheumatic drugs have shown 
beneficial effects on fatigue [29, 46-55]. In spite of this, a qualitative study on how 29 patients with 
RA experience fatigue [4] showed that most patients did not discuss fatigue with clinicians 
explicitly. Not expecting support from health care professionals, they assume that they have to 
manage fatigue alone, as it is part of the disease. Additionally, they describe how they have to find 
their own management strategies by trial and error. These descriptions throw light on patient needs 
not yet met by health care professionals, thus a vast treatment potential lies in the fulfillment of 
these needs. 
In conclusion, the current study has found fatigue to be a sensation that needs to be 
addressed in a holistic and personal perspective, yet some features of fatigue remain unexplained. 
Further studies are needed to find better correlates and improve treatment of RA related fatigue.  
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